Siler H Panowski

US Patent:

20090092551, Apr 9, 2009

Filed:

Jul 17, 2008

Appl. No.:

12/218976

Inventors:

Andrew Dillin - La Jolla CA, US
Hugo Aguilaniu - Lyon, FR
Siler Panowski - San Diego CA, US
Suzanne C. Wolff - Carlsbad CA, US

International Classification:

A61K 49/00
C12Q 1/68
A61K 39/395

US Classification:

424 91, 435 6, 4241301

Abstract:

The roles of the pha-4 and daf-16 genes in diet-restricted induced longevity are described and characterized. Pha-4 acts, e.g., in the absence of daf-16, to increase lifespan, e.g., in nematodes. Given the role that pha-4 and daf-16 play in the mediation of longevity, they represent targets for modulation of life span. Methods of increasing life span and delaying age onset diseases by modulation of pha-4 activity are disclosed, as are screening methods for identifying compounds that modulate pha-4 and/or daf-16 activity. In addition, recombinant animals expressing the pha-4 gene and not the daf-16 gene, and methods of using the pha-4 and/or daf-16 genes to modulate longevity and age-onset diseases are described.

US Patent:

20220409665, Dec 29, 2022

Filed:

Jun 15, 2022

Appl. No.:

17/841041

Inventors:

- South San Francisco CA, US
Siler PANOWSKI - Berkeley CA, US
Barbra Johnson SASU - San Francisco CA, US
Cesar Adolfo SOMMER - San Mateo CA, US
Surabhi SRIVATSA SRINIVASAN - San Francisco CA, US
Thomas John VAN BLARCOM - Oakland CA, US
Shanshan LANG - San Mateo CA, US

International Classification:

A61K 35/17
C07K 16/28
A61P 35/00

Abstract:

Provided herein are CD70-binding proteins comprising a CD70-binding domain and a transmembrane domain, engineered immune cells comprising the CD70-binding proteins, and methods of making and using the same. Also provided herein are engineered immune cells e.g. CAR (chimeric antigen receptor) T cells for administration to patients to treat cancer (e.g., solid tumors and hematologic tumors) and other unwanted conditions. The cells are engineered to functionally express a first antigen binding molecule e.g. a CD70 CAR and a second antigen binding molecule e.g. a second CAR that binds a target molecule characteristic of the cancer or other disease or unwanted condition. The cells may be further engineered to reduce the functional expression level of one or more of TRAC, CD52 and CD70. Also provided are methods of making and using the engineered cells, compositions and kits comprising them, and methods of treating by administering them.

US Patent:

20220227832, Jul 21, 2022

Filed:

Dec 21, 2021

Appl. No.:

17/557654

Inventors:

- SOUTH SAN FRANCISCO CA, US
- NEW YORK NY, US
Michael Thomas BETHUNE - Castro Valley CA, US
Siler PANOWSKI - Berkeley CA, US
Nguyen TAN - Berkeley CA, US
Yi ZHANG - Foster City CA, US
Barbra Johnson SASU - San Francisco CA, US
Zhe LI - Burlingame CA, US

International Classification:

C07K 14/725
C07K 14/705
C12N 15/79
C07K 19/00

Abstract:

A reversibly gated effector polypeptide e.g. a chimeric antigen receptor (protease-activating CD45-gate CAR) comprising an extracellular CD45 recruiting domain, a protease-cleavable linker, and a polypeptide comprising an extracellular ligand binding domain, a transmembrane domain, and an intracellular domain. Nucleic acids including vectors and expression vectors that encode the protease-activating CD45-gate CAR and cells including immune cells such as T cells that comprise and express the nucleic acids. Methods of treatment of various conditions including various forms of cancer comprising administering the cells including CAR T cell therapy. In some embodiments, the CD45 gate at least partially inhibits activation of the protease-activating CD45-gate CAR when the protease-activating CD45-gate CAR binds antigen. The inhibition is at least partially diminished, relieved and/or eliminated when the protease-activating CD45-gate CAR is exposed to a protease that can cleave the linker.

US Patent:

20230041456, Feb 9, 2023

Filed:

Jun 17, 2022

Appl. No.:

17/843616

Inventors:

- New York NY, US
Niranjana NAGARAJAN - Oakland CA, US
Siler PANOWSKI - Berkeley CA, US
Yoon PARK - Seoul, KR
Tao SAI - Foster City CA, US
Barbra SASU - San Francisco CA, US
Thomas VAN BLARCOM - Oakland CA, US
Mathilde DUSSEAUX - Creteil, FR
Roman GALETTO - Paris, FR

International Classification:

C07K 16/28
A61K 39/00
C07K 14/725
A61P 35/02
A61P 35/04

Abstract:

The disclosure provides CARs (CARs) that specifically bind to CD70. The disclosure further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The disclosure further relates to therapeutic methods for use of these CARs and engineered immune cells comprising these CARs for the treatment of a condition associated with malignant cells expressing CD70 (e.g., cancer).

US Patent:

20210260118, Aug 26, 2021

Filed:

Feb 24, 2021

Appl. No.:

17/183689

Inventors:

- South San Francisco CA, US
Siler PANOWSKI - Berkeley CA, US
Cesar Adolfo SOMMER - San Mateo CA, US
Thomas John VAN BLARCOM - Oakland CA, US
Barbra Johnson SASU - San Francisco CA, US
Arun BALAKUMARAN - Westfield NJ, US

International Classification:

A61K 35/17
C07K 14/715
C07K 16/28
C12N 15/86
A61P 35/00

Abstract:

Provided here are engineered immune cells that comprise a constitutively active chimeric cytokine receptor (CACCR) and a B-cell maturation antigen (BCMA) specific chimeric antigen receptor (CAR). Also provided herein are engineered immune cells that comprise one or more nucleic acids e.g. a bicistronic vector such as a viral vector that encode the CACCRs and BCMA CARs and engineered immune cells e.g. engineered autologous or allogeneic T cells that express both CACCRs and BCMA CARs from the nucleic acids. When present on chimeric antigen receptor (CAR)-bearing engineered immune cells, the CACCRs allow for increased immune cell activation, proliferation, persistence, and/or potency. Further provided herein are methods of making and using the engineered immune cells described herein, such as methods of treating a disease or condition by administering at least one appropriate dose of the cells to a patient suffering from the condition.

US Patent:

20210107979, Apr 15, 2021

Filed:

Feb 27, 2020

Appl. No.:

16/802822

Inventors:

- South San Francisco CA, US
- New York NY, US
Siler PANOWSKI - Berkeley CA, US
Barbra Johnson SASU - San Francisco CA, US

International Classification:

C07K 16/28
C12N 15/63
A61P 35/00

Abstract:

Provided herein are DLL3 binding agents and chimeric antigen receptors (CARs) comprising a DLL3 binding molecule that specifically binds to DLL3; and immune cells comprising these DLL3-specific CARs, e.g., CAR-T cells. Also provided are methods of making and using DLL3-specific CARs, and immune cells comprising DLL3-specific CARs.

US Patent:

20210061881, Mar 4, 2021

Filed:

Aug 28, 2020

Appl. No.:

17/005757

Inventors:

- South San Francisco CA, US
Siler PANOWSKI - Berkeley CA, US
Thomas John VAN BLARCOM - Oakland CA, US
Shanshan LANG - San Mateo CA, US
Barbra Johnson SASU - San Francisco CA, US

International Classification:

C07K 14/71
C12N 15/86
C12N 5/0783
A61K 35/17

Abstract:

Provided herein are chimeric cytokine receptors bearing a binding domain capable of binding a TGF-β ligand or a TGF-β receptor antibody. When present on chimeric antigen receptor (CAR)-bearing immune cells (CAR-T-cells), such receptors allow for increased CAR-T cell expansion, activity and persistence, constitutively and/or through engagement of a TGF-β ligand or a TGF-β receptor antibody. Also provided are methods of making and using the chimeric cytokine receptors described herein.

US Patent:

20200291090, Sep 17, 2020

Filed:

Feb 28, 2020

Appl. No.:

16/804917

Inventors:

- South San Francisco CA, US
Thomas John VAN BLARCOM - Oakland CA, US
Siler PANOWSKI - Berkeley CA, US
Barbra Johnson SASU - San Francisco CA, US

International Classification:

C07K 14/715
C07K 16/40
C12N 5/0783
C12N 7/00
C12N 15/86
A61K 35/17
A61P 35/00

Abstract:

Provided herein are constitutively active chimeric cytokine receptors (CACCRs). When present on chimeric antigen receptor (CAR)-bearing immune cells, such CACCRs allow for increased immune cell activation, proliferation, persistence, and/or potency. Also provided are methods of making and using the CACCRs described herein.